This medicine is authorised for use in the European Union.


Bosulif is a cancer medicine that is used to treat chronic myeloid leukaemia (CML), a cancer of the white blood cells, in adults with a special chromosome in their cells called the Philadelphia chromosome.

It is used to treat three stages of CML called ‘chronic phase’, ‘accelerated phase’ and ‘blast phase’ in patients who have already been treated with one or more tyrosine kinase inhibitors (medicines for CML which work in a similar way to Bosulif), and when the tyrosine kinase inhibitors called dasatinib, imatinib and nilotinib are not suitable.

Bosulif is also used to treat newly diagnosed patients who are in the ‘chronic phase’ of CML.

Bosulif contains the active substance bosutinib.

This EPAR was last updated on 17/05/2023

Authorisation details

Product details
Agency product number
Active substance
bosutinib (as monohydrate)
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Leukemia, Myeloid
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Boulevard de la Plaine 17
1050 Bruxelles

Product information

16/05/2023 Bosulif - EMEA/H/C/002373 - IAIN/0056

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Antineoplastic agents

  • Protein kinase inhibitors

Therapeutic indication

Bosulif is indicated for the treatment of adult patients with:

  • newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating